PP122 The Feasibility Assessment For Domestic Introduction Of Newborn Pulse Oximetry Screening For Critical Congenital Heart Disease

IF 2.6 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES International Journal of Technology Assessment in Health Care Pub Date : 2023-12-14 DOI:10.1017/s0266462323002362
Miyoung Choi, Jimin Kim, Byung Min Choi, Jeonghee Shin, Chanmi Park, Gisu Ha, Hong Joo Shin, Eui Kyung Choi
{"title":"PP122 The Feasibility Assessment For Domestic Introduction Of Newborn Pulse Oximetry Screening For Critical Congenital Heart Disease","authors":"Miyoung Choi, Jimin Kim, Byung Min Choi, Jeonghee Shin, Chanmi Park, Gisu Ha, Hong Joo Shin, Eui Kyung Choi","doi":"10.1017/s0266462323002362","DOIUrl":null,"url":null,"abstract":"<span>Introduction</span><p>Critical congenital heart disease (CCHD) refers to a group of heart defects that cause serious, life-threatening symptoms in the neonatal period and requires timely surgical or catheter interventions. We reviewed evidence for incorporating a mandatory neonatal CCHD screening test as a national public health project for all neonates born in Korea by analyzing the validity and cost-effectiveness of neonatal CCHD screening using pulse oximetry in Korea.</p><span>Methods</span><p>We performed a rapid literature review to establish models for the diagnostic accuracy and economic evaluation of pulse oximetry. Also, we analyzed the prevalence, mortality, and medical expenditure for different types of CCHD using the national health insurance (NHI) data. We analyzed the cost-effectiveness of pulse oximetry by comparing the group of neonates who received a combination of a physical examination and pulse oximetry, and group of neonates who only received a physical examination. For the cost-effectiveness analysis for the CCHD screening test in this study, we used a duration of one year, diagnostic accuracy as the clinical endpoint, and Life Year Gain (LYG) as the effectiveness indicator.</p><span>Results</span><p>We used recent systematic review he pooled sensitivity can be enhanced from 76.5 percent (pulse oximetry alone) to 92 percent (combined with physical examination). We used a total of 2,334 neonates with CCHD data for the economic model. Our analysis revealed that adding pulse oximetry to the routine neonatal physical examination leads to 2.34 of LYG and a cost difference of USD1,080,602, showing a ICER of KRW610,063,240 (USD461,857)/LYG.</p><span>Conclusions</span><p>Considering the benefit of LYG and cost of reducing the complications and after effects of newborns with CCHD who survived early diagnosis, it is considered to be worthwhile in Korea for a mandatory screening test.</p>","PeriodicalId":14467,"journal":{"name":"International Journal of Technology Assessment in Health Care","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Technology Assessment in Health Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/s0266462323002362","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Critical congenital heart disease (CCHD) refers to a group of heart defects that cause serious, life-threatening symptoms in the neonatal period and requires timely surgical or catheter interventions. We reviewed evidence for incorporating a mandatory neonatal CCHD screening test as a national public health project for all neonates born in Korea by analyzing the validity and cost-effectiveness of neonatal CCHD screening using pulse oximetry in Korea.

Methods

We performed a rapid literature review to establish models for the diagnostic accuracy and economic evaluation of pulse oximetry. Also, we analyzed the prevalence, mortality, and medical expenditure for different types of CCHD using the national health insurance (NHI) data. We analyzed the cost-effectiveness of pulse oximetry by comparing the group of neonates who received a combination of a physical examination and pulse oximetry, and group of neonates who only received a physical examination. For the cost-effectiveness analysis for the CCHD screening test in this study, we used a duration of one year, diagnostic accuracy as the clinical endpoint, and Life Year Gain (LYG) as the effectiveness indicator.

Results

We used recent systematic review he pooled sensitivity can be enhanced from 76.5 percent (pulse oximetry alone) to 92 percent (combined with physical examination). We used a total of 2,334 neonates with CCHD data for the economic model. Our analysis revealed that adding pulse oximetry to the routine neonatal physical examination leads to 2.34 of LYG and a cost difference of USD1,080,602, showing a ICER of KRW610,063,240 (USD461,857)/LYG.

Conclusions

Considering the benefit of LYG and cost of reducing the complications and after effects of newborns with CCHD who survived early diagnosis, it is considered to be worthwhile in Korea for a mandatory screening test.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PP122 国内引入新生儿脉搏氧饱和度筛查重症先天性心脏病的可行性评估
危重型先天性心脏病(CCHD)是指一组心脏缺陷,在新生儿期引起严重的、危及生命的症状,需要及时的手术或导管干预。我们通过分析韩国脉搏血氧仪筛查新生儿CCHD的有效性和成本效益,回顾了将强制性新生儿CCHD筛查试验纳入韩国所有新生儿国家公共卫生项目的证据。方法快速查阅文献,建立脉搏血氧仪的诊断准确性和经济性评估模型。此外,我们还利用国民健康保险(NHI)数据分析了不同类型CCHD的患病率、死亡率和医疗支出。我们通过比较接受体格检查和脉搏血氧测定相结合的新生儿组和只接受体格检查的新生儿组来分析脉搏血氧测定的成本效益。本研究中CCHD筛查试验的成本-效果分析,我们以持续时间为1年,诊断准确性为临床终点,生命年增益(LYG)为有效性指标。结果我们使用最近的系统评价,将敏感性从76.5%(单独脉搏血氧测定)提高到92%(结合体格检查)。我们在经济模型中使用了2334名有CCHD数据的新生儿。我们的分析显示,在新生儿常规体检中加入脉搏血氧仪导致LYG为2.34,成本差异为1,080,602美元,ICER为610,063,240韩元(461,857美元)/LYG。结论考虑到LYG的益处和减少早期诊断存活的CCHD新生儿并发症和后遗症的成本,在韩国进行强制性筛查试验是值得的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Technology Assessment in Health Care
International Journal of Technology Assessment in Health Care 医学-公共卫生、环境卫生与职业卫生
CiteScore
4.40
自引率
15.60%
发文量
116
审稿时长
6-12 weeks
期刊介绍: International Journal of Technology Assessment in Health Care serves as a forum for the wide range of health policy makers and professionals interested in the economic, social, ethical, medical and public health implications of health technology. It covers the development, evaluation, diffusion and use of health technology, as well as its impact on the organization and management of health care systems and public health. In addition to general essays and research reports, regular columns on technology assessment reports and thematic sections are published.
期刊最新文献
Development of an MCDA Framework for Rare Disease Reimbursement Prioritization in Malaysia. Experiences of patient organizations' involvement in medicine appraisal and reimbursement processes in Finland - a qualitative study. PP78 Real-World Trends And Medical Costs Of Stroke After Transcatheter Aortic Valve Implantation In Korea: A Nationwide, Population-Based Study Can requests for real-world evidence by the French HTA body be planned? An exhaustive retrospective case-control study of medicinal products appraisals from 2016 to 2021. A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1